Results 151 to 160 of about 60,209 (283)

A RANDOMIZED TRIAL OF SIROLIMUS, CYCLOSPORINE AND PREDNISONE VS CYCLOSPORINE - PREDNISONE ALONE IN RECIPIENTS OF MISMATCHED FIRST KIDNEY GRAFTS: RESULTS AT ONE YEAR

, 1999
A. S. Macdonald
openalex   +1 more source

Hyperlipidaemia and post‐heparin lipase activities in renal transplant recipients treated with sirolimus or cyclosporin A [PDF]

, 2000
Ziad A. Massy, J.‐P. De Bandt, Emmanuel Morélon, Marc Thévenin, Bernard Lacour, Henri Kreis   +5 more
openalex   +1 more source

ONE-YEAR OUTCOME AFTER STEROID WITHDRAWAL FROM A SIROLIMUS-CYCLOSPORINE-PREDNISONE REGIMEN IN CADAVER- AND LIVING-DONOR RECIPIENTS.

, 1998
B D Kahan, Mark D. Pescovitz, Gcw Chan, J Neylan, Bruce A. Julian, S. M. Katz, C.T. Van Buren   +6 more
openalex   +1 more source

Transcriptomic signatures and network‐based methods uncover new senescent cell anti‐apoptotic pathways and senolytics

The FEBS Journal, Volume 292, Issue 8, Page 1950-1971, April 2025.
This study identifies new senescent cell antiapoptotic pathways (SCAPs) by analyzing transcriptomic signatures and co‐expression networks. We uncover novel antiapoptotic pathways, called SCAPs, and propose potential senolytic drugs, including Fluorouracil, which targets key SCAPs.
Samael Olascoaga, Mina Konigsberg, Jesús Espinal‐Enríquez, Hugo Tovar, Félix Matadamas‐Martínez, Jaime Pérez‐Villanueva, Norma Edith López‐Diazguerrero   +6 more
wiley   +1 more source

SIROLIMUS EXACERBATES CsA-INDUCED NEPHROTOXICITY BY RAISING CsA BLOOD TROUGH LEVELS, BUT DOES NOT IMPAIR RENAL FUNCTION BY A PHARMACODYNAMIC INTERACTION

, 1999
Hemangshu Podder, Stanislaw M. Stepkowski, Kimberly L. Napoli, B D Kahan   +3 more
openalex   +1 more source

New Scenarios in Liver Transplantation for Hepatocellular Carcinoma

Liver International, Volume 45, Issue 4, April 2025.
ABSTRACT Background and Aims Despite liver transplantation (LT) is considered the optimal treatment for hepatocellular carcinoma (HCC), particularly in patients with impaired liver function, the shortage of donors has forced the application of very restrictive criteria for selecting ideal candidates for whom LT can offer the best outcome.
Ezequiel Mauro, Manuel Rodríguez‐Perálvarez, Antonio D'Alessio, Gonzalo Crespo, Federico Piñero, Eleonora De Martin, Jordi Colmenero, David James Pinato, Alejandro Forner   +8 more
wiley   +1 more source

EFFECT OF SIROLIMUS ON PLASMA LIPID AND LIPOPROTEIN LEVELS AND METABOLISM IN RENAL TRANSPLANT PATIENTS

, 1999
Joel D. Morrisett, Christie M. Ballantyne, Henry J. Pownall, Antone R. Opekun, Jonathan S. Jaffe, Suzanne Oppermann, B D Kahan   +6 more
openalex   +1 more source

THE ROLE OF CLONAL DELETION IN PROLONGING SKIN ALLOGRAFT SURVIVAL IN MICE TREATED WITH ANTILYMPHOCYTE SERUM (ALS), DONOR SPECIFIC BONE MARROW (BM) AND SIROLIMUS (SIR)

, 1998
Douglas A. Hale, Rita Gottschalk, Takashi Maki, Anthony P. Monaco   +3 more
openalex   +1 more source

PHARMACOKINETICS/PHARMACODYNAMIC PROFILES OF AFRICAN AMERICANS (AA) IN A PHASE II RANDOMIZED PLACEBO-CONTROLLED TRIAL OF SIROLIMUS (RAPA) IN RENAL TRANSPLANTATION

, 1999
Rakesh Sindhi, James M. Jaffe, Mark J. Caulfield   +2 more
openalex   +1 more source

SIROLIMUS-TACROLIMUS COMBINATION IMMUNOSUPPRESSION FOR KIDNEY-PANCREAS TRANSPLANTATION: EFFECT ON RENAL FUNCTION.

, 2000
Anastasio Salazar, Vivian C. McAlister, Bryce Kiberd, Mohamed F. Al-Keriby, H Bitter-Suermann, Allan S. MacDonald   +5 more
openalex   +1 more source